Press release & events

-

Explicyte was pleased to participate to the AACR Virtual Annual Meeting, last week to get breakthroughs in Immuno-Oncology and to present our posters featuring our capacities / platforms that support drug discovery.

By setting new facilities within the cancer center “Institut Bergonié”, Explicyte - in addition to its preclinical research capabilities - strengthens its development towards clinical translational research, to provide new services based on multiparametric experimental biomarker analysis, for target identification and monitoring of the immune response in the context of clinical trials.

Our syngeneic glioma mouse model, based on the intracranial inoculation of Luc2-expressing GL261 cells and bioluminescence imaging for tumor growth monitoring, represents a suitable tool for chemo- and immunotherapy assessment. It closely mimics the human disease in terms of tumor progression and anti-tumor response, and recapitulates glioblastoma characteristic features including among others tumor immune cell infiltration and tumor-induced immunosuppression.

Bordeaux, FRANCE, March 24, 2019: Explicyte and Institut Bergonié, have entered into a collaboration to conjointly drive a translational research program aiming at identifying resistance mechanisms to immune checkpoint inhibitors in cancer patients.

We will be attending the AACR Annual Meeting in Atlanta, from March 29 to April 3, 2019. We will be glad to take this opportunity to meet you there, describe our service offerings and approach your research projects.

Eurostars, a European joint programme, co-funded from the national budgets of several EUREKA countries and by the European Union through Horizon 2020 has awarded, through a highly-competitive selection process, the Project “A novel modified natural killer (NK) cell immunotherapy for the treatment of solid tumours” – MODIFY-NK.

Two former key executives of preclinical CRO Fluofarma will join Explicyte in March 2016. This new brand, powered by ImmuSmol, offers preclinical contract research services in immuno-oncology, and intends to release specialty research services in the field of neurobiology by the end of 2016.